A Translational Pharmacology Framework to Drive Antifibrotic Programs

• Building pathobiology maps from large human transcriptomic, proteomic, and clinical biomarker datasets to identify disease-associated biological modules
• Mapping human pathobiology onto in vitro and in vivo data to identify relevant translational models
• Integrating interventional pathway-specific biomarker data into a self-reinforcing framework for driving programs toward the clinic

Speakers:

Bernard Allan

Executive Director & Head of Liver Disease Research & Drug Discovery, GI-Ddu

Takeda Pharmaceutical